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Percutaneously inserted central catheters (PICCs) are often used in neonatal medicine.  Venous throm-
bosis (VT) is one of the complications associated with PICC use.  According to some reports,  fresh 
frozen plasma (FFP) may be a risk factor for VT.  The purpose of this study was to determine 
whether FFP use is associated with VT in extremely low birth weight infants (ELBWIs).  We per-
formed a matched case-control study on risk factors for VT in ELBWIs born over a period of 5 years 
in the neonatal intensive care unit of a tertiary hospital.  Controls were infants from the unit matched 
for gestational age and birth weight.  We performed univariate analyses and created receiver operat-
ing characteristic (ROC) curves for the cut-oﬀ values of continuous parameters such as FFP.  We also 
conducted multivariate conditional logistic regression analysis and calculated adjusted odds ratios and 
their 95ｵ conﬁdence intervals.  Thirteen VT cases and 34 matched controls were examined.  Using an 
ROC curve,  FFP by day 5＞50mL/kg was selected as the cut-oﬀ value.  In multivariate conditional 
logistic regression analysis,  FFP by day 5＞50mL/kg exhibited an adjusted odds ratio of 5.88 (95ｵ 
conﬁdence interval: 1.12-41.81,  p＝0.036).  FFP by day 5＞50mL/kg may be a risk factor for VT in 
ELBWIs.
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ercutaneously inserted central catheters (PICCs) 
are often used in neonatal medicine.  Venous 
thrombosis (VT) is a complication associated with 
PICC use.  In a Canadian multi-center study,  the 
incidence of VT in babies admitted to the neonatal 
intensive care unit (NICU) was 0.24ｵ [1].  In Holland,  
the incidence of VT in neonates has been reported to 
be 0.15ｵ [2].  A nationwide postal questionnaire 
survey of PICC complications in Japanese neonates 
uncovered only 10 symptomatic thrombosis cases in 5 
years [3].  According to an unpublished hospital 
report,  the incidence of VT in babies admitted to the 
NICU of Osaka Medical Center and the Research 
Institute for Maternal and Child Health (OMC) in the 
last 5 years was 1.2ｵ.  The incidence of VT in 
extremely low birth weight infants (ELBWIs) was 
6.1ｵ,  which is high in comparison to previously 
reported rates.
　 Risk factors for VT include indwelling catheters 
P
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(e.g.,  PICCs),  hypercoagulation,  polycythemia,  hypo-
perfusion,  infection and maternal disease [1,  2,  4-6].  
Fresh frozen plasma (FFP) contains coagulation fac-
tors and platelet-derived microparticles that partici-
pate in clot formation [7].  Excessive FFP may cause 
an increase in the concentration of these components.  
Patiroglu et al.  reported middle cerebral artery throm-
bosis after FFP and recombinant activated factor VII 
infusion in a patient with hypoﬁbrinogenemia [8].  
Puetz et al.  reported that 7ｵ of patients treated for 
coagulopathy or bleeding with FFP infusion develop 
thrombosis [9].  These 2 reports suggest that FFP 
may be associated with VT.  Although FFP is often 
used as a volume expander in treating ELBWIs,  some 
guidelines advise against the use of FFP for this 
purpose [10].  Accordingly,  the aim of the present 
study was to determine whether frequent FFP use is 
a risk factor for VT in ELBWIs.
Materials and Methods
　 We performed a matched case-control study on risk 
factors for VT in ELBWIs born over a period of 5 
years (from April 1,  2004 to March 31,  2009) at the 
NICU of OMC.  Group A (n＝13),  the case group,  
consisted of ELBWIs with VT diagnosed by ultra-
sound or autopsy.  Ultrasound was routinely performed 
at least once a week up to day 28 post birth.  An 
additional test for VT was performed when thrombo-
cytopenia occurred without infection.  The searching 
sites for ultrasound were the superior vena cava 
(SVC),  the inferior vena cava (IVC) and the heart.  
Group B (n＝34),  the control group,  consisted of 
NICU infants matched for gestational age and birth 
weight.  For each case subject,  a maximum of three 
ELBWI controls were selected whose gestational age 
(every 2 weeks) and birth weight (every 100g) were 
matched.
　 We retrospectively collected perinatal data for the 
ﬁrst 5 days of life,  using the following parameters 
general characteristics (sex,  gestational age,  birth 
weight,  height,  head circumference and Apgar score),  
PICC factors (PICC tip in right atrium and FFP or 
red cell concentrates in mannitol-adenine-phosphate 
(MAP) solution through the PICC),  hypercoagulation 
factors (coagulation test at birth and total amount of 
platelet concentrate and FFP by day 5),  polycythemia 
factors (hemoglobin (Hb) at birth and on day 3 and 
total amount of MAP by day 5),  hypoperfusion factors 
(enteral feeding and urine output on day 5,  rather than 
supra vena cava or IVC ﬂow),  infection factors 
(immunoglobulin M (IgM) at birth,  C-reactive protein 
(CRP) at birth and on day 3,  Blanc classiﬁcation of 
placenta and sepsis by day 5),  maternal disease fac-
tors (pregnancy-induced hypertension,  diabetes melli-
tus,  systemic lupus erythematosus,  and antiphospho-
lipid syndrome),  as well as complete blood count 
(CBC),  pH,  pCO2,  base excess (BE) at birth,  and 
total amount of calcium on day 5.  Some factors either 
lacked data or data were outside the range of mea-
surement.
　 Data are expressed as mean and standard deviation 
(SD) for continuous variables and frequency and per-
centage (ｵ) for binary or categorical variables.  The 
matched case-control study was analyzed using condi-
tional logistic regression.  We ﬁrst performed uni-
variate analyses of the variables in conditional logistic 
regression.  We then created a receiver operating 
characteristic (ROC) curve for cut-oﬀ values of con-
tinuous parameters such as FFP,  and calculated sen-
sitivity,  speciﬁcity,  positive likelihood ratio,  and area 
under curve (AUC).  A multivariable model was con-
structed using selection criteria with a signiﬁcance 
level of ＜0.2 in univariate analysis,  given the small 
size of the study group.  Variables with missing data 
were eliminated from the model.  We performed mul-
tivariate conditional logistic regression analysis and 
calculated adjusted odds ratios (ORs) and their 95ｵ 
conﬁdence intervals (95ｵ CIs).  Apgar scores at 1 
and 5min were similar,  so only the 5-min score was 
used.  Two cases with ﬁbrinogen levels of ＜50mg/
dL were assigned values of 0.  Fibrinogen values were 
divided by 100 because the indication for FFP is a 
ﬁbrinogen value of less than 100mg/dL in some guide-
lines [10].  The ﬁbrinogen degradation products (FDP) 
factor was eliminated due to the large number of miss-
ing data.  A new category was created for gestational 
age and birth weight because the 2 variables were 
related and data were sparse.  In the appropriate for 
gestational age (AGA) group,  birth weight was ＞400g 
at 22 weeks,  ＞500g at 23 weeks,  ＞600g at 24 
weeks,  ＞700g at 25 weeks,  ＞800g at 26 weeks,  and 
＞900g at 27 weeks.  The small for gestational age 
(SGA) group comprised the remaining cases.  BE was 
divided by 5; when asphyxia was assessed,  the cut-oﬀ 
value for BE was －12 [11].  In the present study,  
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mean BE values were －7.5 and －9.3 in Groups A and 
B,  respectively.  The diﬀerence between the mean and 
－12 was approximately 5.  Sodium bicarbonate was 
used when BE was ＜－5.  SGA infants suﬀer coagula-
tion abnormality and require signiﬁcant amounts of 
FFP [12].  Thus,  sensitivity analysis was performed 
after eliminating cases of severe SGA (Wt ＜－2 SD).
　 Statistical analysis was performed using JMP 7.0.1 
(SAS Institute,  Inc.,  Cary,  NC,  USA).  This study 
was approved by the OMC ethics committee.
Results
　 Groups A and B had 13 and 34 cases,  respec-
tively.  Gestational ages were 24.8 (1.4) weeks and 
24.6 (1.0) weeks,  and birth weights were 644 (103) g 
and 657 (97) g in Groups A and B,  respectively.  FFP 
by day 5 values were 55 (34) mL/kg and 52 (58) mL/
kg in Groups A and B,  respectively,  and minimum,  
25ｵtile,  median,  75ｵtile and maximum FFP by day 
5 were 0,  26,  53,  78,  118 and 0,  11.5,  40.5,  80.6,  
305.  An FFP by day 5 value of ＜51mL/kg corre-
sponded to sensitivity,  speciﬁcity,  positive likelihood 
ratio and AUC values of 0.69,  0.65 (1－speciﬁcity＝
0.35),  0.34 and 0.59,  respectively.  An FFP value of 
50mL/kg was chosen as the cut-oﬀ value.  Nine group 
A cases (69ｵ) and 12 group B cases (35ｵ) had an 
FFP by day 5 value of ＞50mL/kg (OR: 4.13; 95ｵ 
CI: 1.05-16.26; p＝0.052).
　 Perinatal factors,  laboratory data at birth and 
laboratory and clinical data on days 3 and 5 are shown 
in Tables 1-3,  respectively,  for VT patients and 
controls.  In VT cases,  the mean (SD) detection day 
was 28 (19),  and the earliest was day 6.  The detec-
tion sites were 1 SVC,  11 IVC and 1 pulmonary 
artery.  The methods of detection were 6 thrombocy-
topenia,  6 routine ultrasound and 1 autopsy.  The 
autopsy case had a sudden SpO2 decrease and throm-
bus in the pulmonary artery,  which was the cause of 
death.
　 The number of cases (blank/outside the measure-
ment range) for each variable were as follows: birth 
height (2/0),  birth head circumference (2/0),  pro-
thrombin time (PT) (1/2),  activated partial thrombo-
plastin time (APTT) (0/5),  ﬁbrinogen (0/2),  FDP 
(10/0),  antithrombin III (AT-III) (10/1),  IgM (1/23),  
CRP at birth (0/29) and CRP on day 3 (0/13).  The 
following factors exhibited p-values of ＜0.2: sex,  
Apgar scores at 1 and 5min,  ﬁbrinogen,  FDP,  FFP 
by day 5＞50mL/kg,  day 3 Hb and BE.
　 Multivariate conditional logistic regression analy-
sis (Table 4) yielded the following adjusted ORs (95ｵ 
CI): FFP by day 5＞50mL/kg,  5.88 (1.12-41.81);  
and BE/5,  3.95 (1.41-14.39).
　 SGA/AGA cases in groups A and B were 5/8 and 
10/24,  respectively.  For sensitivity analysis,  we 
eliminated 6 infants with severe SGA (2 VT cases 
and 4 controls).  The mean (SD) of FFP by day 5 
(mL/kg) was 54 (26) in Group A and 45 (39) in Group 
B (mean diﬀerence,  9.33 (95ｵCI －16.23-34.89); p
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Table 1　 Perinatal factors
Group A (n＝13) Group B (n＝34) OR or MD (95% CI) p-value
Female 9 (69%) 13 (38%) 3.63 (0.93-14.24) 0.101
Gestational age (weeks) 24.8 (1.4) 24.6 (1.0) 0.21 (－0.50-0.92) 0.561
Birth weight (g) 644 (103) 657 (97) －12.79 (－77.74-52.15) 0.693
Birth height (cm)＊ 31.3 (1.3) 30.5 (2.1) 0.82 (－0.47-2.11) 0.204
Birth head circumference (cm)＊ 22.2 (1.2) 21.9 (1.0) 0.37 (－0.36-1.10) 0.311
Apgar score at 1min 4.5 (1.3) 3.7 (1.8) 0.76 (－0.36-1.87) 0.180
Apgar score at 5min 6.8 (1.5) 5.8 (2.2) 0.98 (－0.35-2.30) 0.146
PIH 1 (7.7%) 0 (0%) 1 (-) ―
DM 0 (0%) 1 (2.9%) －1 (-) ―
SLE 0 (0%) 0 (0%) 0 (-) ―
APS 0 (0%) 0 (0%) 0 (-) ―
Placental infection,  Blanc 3 5 (38%) 18 (53%) 0.56 (0.15-2.05) 0.374
Data are expressed as mean (standard deviation) or case number (percentage).
OR,  odds ratio; MD,  mean diﬀerence; CI,  conﬁdence interval; PIH,  pregnancy-induced hypertension; DM,  diabetes mellitus; SLE,  
systemic lupus erythematosus; APS,  antiphospholipid syndrome.
＊Cases with (no data/outside the measurement range): birth height (2/0),  birth head circumference (2/0).
＝0.465).  From the ROC curve,  the AUC was the 
biggest when FFP was 51.  We set 50mL/kg as the 
cut-oﬀ value.  OR was 5.33 (95ｵCI 1.16-24.60; p＝
0.036) in FFP by day 5＞50mL/kg.
Discussion
　 Our clinical hypothesis was that frequent use of 
FFP may contribute to VT in ELBWIs.  One of the 
risk factors for VT is hypercoagulation [5].  FFP 
contains several coagulation factors and platelet-
derived microparticles [7],  and some previous studies 
have shown that FFP is associated with VT [8,  9].  
In the present study,  the adjusted OR of FFP by day 
5＞50mL/kg was high at 5.88.  Thus,  excessive FFP 
may be a risk factor for VT.
　 The mean (SD) values of FFP by day 5 in Groups 
A and B were 55 (34) mL/kg and 52 (58) mL/kg,  
respectively.  The diﬀerence of mean seemed small,  
but variability was diﬀerent and the diﬀerence may 
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Table 2　 Laboratory data at birth
Group A (n＝13) Group B (n＝34) MD (95% CI) p-value
WBC (103/µL) 20.1 (21.1) 23.1 (18.9) －3.01 (－15.84-9.82) 0.639
Hb (g/dL) 13.6 (2.6) 14.0 (2.3) －0.43 (－1.98-1.12) 0.577
Platelet (103/µL) 211 (60) 221 (84) －10.45 (－61.90-41.00) 0.684
pH 7.227 (0.109) 7.183 (0.112) 0.044 (－0.029-0.117) 0.230
pCO2 (mmHg) 51.3 (11.7) 59.3 (35.1) －7.94 (－28.07-12.19) 0.431
Base Excess (mmol/L) －7.5 (4.1) －9.3 (4.1) 1.77 (－0.92-4.46) 0.192
PT (%)＊ 42 (7.6) 45 (15.1) －3.05 (－12.30-6.20) 0.509
APTT (s)＊ 102 (24) 92 (25) 10.68 (－7.12-28.50) 0.233
Fibrinogen (mg/dL)＊ 130 (93) 194 (155) －64.38 (－160.83-32.08) 0.185
FDP (µg/mL)＊ 22.7 (44.5) 7.7 (7.3) 15.02 (－3.26-33.30) 0.104
AT-III (%)＊ 22.3 (4.2) 24.7 (13.3) －2.46 (－10.51-5.60) 0.539
CRP (mg/dL)＊ 0.35 (0.35) 0.34 (0.39) 0.015 (－0.61-0.64) 0.960
IgM (mg/dL)＊ 7.7 (4.8) 15.2 (23.6) －7.51 (－29.96-14.95) 0.495
Data are expressed as mean (standard deviation).
MD,  mean diﬀerence; CI,  conﬁdence interval; WBC,  white blood cell; PT,  prothrombin time; APTT,  activated partial thromboplastin 
time; FDP,  ﬁbrinogen degradation products; AT-III,  antithrombin III; CRP,  C-reactive protein.
＊Cases with (no data/outside the measurement range): PT (1/2),  APTT (0/5),  ﬁbrinogen (0/2),  FDP (10/0),  AT-III (10/1),  CRP (0/29),  
IgM (1/23).
Table 3　 Laboratory and clinical data on days 3 and 5
Group A (n＝13) Group B (n＝34) OR or MD (95% CI) p-value
Hb on day 3 (g/dL) 12.6 (1.3) 11.4 (1.5) 1.19 (0.24-2.13) 0.015
CRP on day 3 (mg/dL)＊ 0.21 (0.17) 0.44 (0.69) －0.22 (－0.76-0.31) 0.405
Enteral feeding on day 5 (mL/kg/day) 10.5 (3.5) 15.3 (13.3) －4.81 (－13.00-3.40) 0.244
Urine output on day 5 (mL/kg/h) 3.7 (1.5) 4.1 (1.2) －0.39 (－1.23-0.45) 0.352
FFP by day 5 (mL/kg) 55 (34) 52 (58) 3.05 (－31.49-37.59) 0.860
FFP by day 5＞50mL/kg 9 (69%) 12 (35%) 4.13 (1.05-16.26) 0.052
MAP by day 5 (mL/kg) 22 (13) 20 (15) 1.92 (－7.50-11.35) 0.682
FFP or MAP through PICC by day 5 7 (54%) 15 (44%) 1.48 (0.41-5.33) 0.550
Platelet concentrate by day 5 (mL/kg) 0 (0) 3.3 (10) －3.32 (－8.93-2.29) 0.240
PICC tip in right atrium on day 5 2 (15%) 4 (12%) 1.36 (0.22-8.52) 1.000
Calcium by day 5 (mg/kg) 5.2 (1.4) 5.2 (1.5) －0.0079 (－0.98-0.97) 0.987
Sepsis by day 5 0 (0%) 0 (0%) 0 (-) ―
Data are expressed as mean (standard deviation) or case number (percentage).
OR,  odds ratio; MD,  mean diﬀerence; CI,  conﬁdence interval; CRP,  C-reactive protein; FFP,  fresh frozen plasma; MAP,  mannitol-
adenine-phosphate; PICC,  percutaneously inserted central catheter.
＊Cases with (no data/outside the measurement range): CRP on day 3 (0/13).
have aﬀected the prognosis.  Following sensitivity 
analysis,  the mean (SD) values of FFP by day 5 in 
Groups A and B were 54 (26) mL/kg and 45 (39) mL/
kg,  respectively.  Thus,  the diﬀerence in means was 
slightly higher after sensitivity analysis.  A previous 
report suggests that the recommended FFP volume is 
10mL/kg/dose [10].  Based on this,  50mL/kg by day 
5 corresponds to one dose per day,  up to day 5.  
Accordingly,  a high adjusted OR indicates that 
50mL/kg by day 5 may be the critical dose.
　Patients in Group A showed signs or symptoms of 
coagulation perturbations or hemodynamic compro-
mise.  Furthermore,  asphyxia has been reported to 
cause coagulation abnormalities [13].  However,  there 
were no diﬀerences in pH or pCO2 at birth in the VT 
and control patients in the present study.  Apgar 
scores and BE were better in Group A,  and enteral 
feeding and urine output on day 5 were lower in these 
subjects.
　 Fibrinogen at birth was lower and APTT and FDP 
were high in Group A,  while PT and AT-III were 
similar in both groups,  possibly indicating that Group 
A patients were already in a hypercoagulative state at 
birth and that ﬁbrinogen had been consumed.  As a 
result,  a high volume of FFP may have been required.  
Coagulation abnormalities at birth have been reported 
in SGA infants [12].  While there were more SGA 
infants in Group A than in Group B,  the adjusted OR 
of SGA was 0.86 (95ｵ CI: 0.17-3.99).  Furthermore,  
infection can cause increases in ﬁbrinogen [14].  In 
fact,  there were more placental infections in Group B.  
While the observed ﬁbrinogen increase may have been 
caused by infection,  this contradicts the previous 
observation that infection is a risk factor for VT [2].
　 Group A had more females than Group B (adjusted 
OR: 3.89; 95ｵ CI: 0.83-22.11); however,  childhood 
arterial ischemic stroke and cerebral sinovenous 
thrombosis occur more often in males than in females 
[15,  16].  Some causes include increased testoster-
one,  estrogen and prostacyclin.  Accordingly,  gender 
cannot be considered a risk factor.
　 There are a number of limitations worth noting.  
First,  the study included only a small number of VT 
and control cases because data were collected from a 
single hospital.  Second,  a coagulation test on day 5 
would have been useful to determine coagulation sta-
tus.  Finally,  although ultrasound tests were per-
formed routinely,  silent thrombi may have been pres-
ent in Group B.
　 In conclusion,  the results of the present matched 
case-control study suggest that FFP by day 5＞50 
mL/kg may be a risk factor for VT in ELBWIs.
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